Non-small cell lung cancer Cell Models for Research

Lung cancer is the leading cause of cancer-related mortality worldwide, with an estimated 2.2 million new cases and 1.8 million deaths in 2020 (WHO GLOBOCAN). Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases. The 5-year survival rate for NSCLC is about 26% for localized disease, but drops to 7% for distant metastases (NCI SEER). Major risk factors include tobacco smoking, exposure to radon, asbestos, and air pollution, as well as genetic predisposition. The high mortality and heterogeneity underscore the urgent need for advanced research models.

NSCLC is an ideal model for mechanistic studies due to its well-characterized molecular subtypes, extensive public genomic datasets (e.g., TCGA, COSMIC), and the availability of numerous cell lines representing different genetic backgrounds. Key open questions include resistance mechanisms to targeted therapies, the role of tumor microenvironment, and the identification of novel therapeutic targets. Gene-edited cell models enable precise manipulation of genes implicated in NSCLC, facilitating functional validation and drug discovery.

Several pathways are critical in NSCLC pathogenesis:

• • EGFR signaling: Activation of EGFR leads to downstream MAPK and PI3K/AKT pathways, promoting cell proliferation and survival.
• • KRAS signaling: Mutant KRAS constitutively activates RAF/MEK/ERK and PI3K/AKT pathways, driving tumorigenesis.
• • ALK fusion: EML4-ALK fusion leads to constitutive ALK kinase activity, activating multiple signaling cascades.
• • p53 pathway: Loss of TP53 function impairs cell cycle arrest and apoptosis, contributing to genomic instability.

Data from TCGA and COSMIC.

Key deregulated networks in NSCLC include:

• • MAPK/ERK pathway: Activated by EGFR, KRAS, and ALK alterations, leading to uncontrolled proliferation.
• • PI3K/AKT/mTOR pathway: Frequently activated via EGFR, KRAS, or loss of PTEN, promoting survival and metabolism.
• • Wnt/β-catenin pathway: Aberrant activation in a subset of NSCLC, contributing to stemness and metastasis.
• • JAK/STAT pathway: Activated by cytokines and growth factors, influencing immune evasion and inflammation.

These networks are interconnected and represent potential therapeutic targets.

Organoids derived from patient tumors preserve 3D architecture and heterogeneity, offering more physiologically relevant models for drug testing.

• • Patient-derived xenografts (PDX): Implantation of patient tumor tissue into immunodeficient mice, preserving tumor heterogeneity and genetic alterations.
• • Genetically engineered mouse models (GEMM): Conditional knock-in of oncogenic mutations (e.g., Kras G12D) or knockout of tumor suppressors (e.g., Trp53) to mimic human NSCLC.
• • Induced models: Use of carcinogens (e.g., urethane) to induce lung tumors in mice, useful for studying chemical carcinogenesis.

CRISPR-Cas9 technology enables the creation of isogenic cell lines with precise genetic modifications. For example:

• • TP53 knockout: Disruption of TP53 in a wild-type background to study loss-of-function effects.
• • KRAS G12C knock-in: Introduction of the oncogenic KRAS G12C mutation into a wild-type cell line to model constitutive activation.
• • EGFR T790M knock-in: Introduction of the resistance mutation into an EGFR-mutant line to study acquired resistance.

These gene-edited models are commercially available and sequence-verified, providing reliable tools for functional studies and drug development.

Knockout and knock-in cell lines are essential for validating gene function. For instance, knocking out a candidate tumor suppressor gene in NSCLC cells can reveal its role in proliferation or apoptosis. Conversely, introducing an oncogenic mutation can confer growth advantages, enabling the study of downstream signaling and potential therapeutic vulnerabilities.

Isogenic pairs (e.g., EGFR-mutant vs. EGFR-wild-type) are used in high-throughput screens to identify selective inhibitors. Resistance models can be generated by exposing cells to increasing drug concentrations or by introducing known resistance mutations (e.g., EGFR T790M) to study mechanisms and develop next-generation therapies.

CRISPR-based synthetic lethality screens can identify genes that are essential only in the presence of specific mutations. For example, in KRAS-mutant NSCLC, screening for genes whose knockout is lethal can reveal novel therapeutic targets. Gene-edited models also facilitate the discovery of predictive biomarkers by correlating genetic alterations with drug response.